0001209191-23-054169.txt : 20231102 0001209191-23-054169.hdr.sgml : 20231102 20231102165248 ACCESSION NUMBER: 0001209191-23-054169 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231031 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Roth David CENTRAL INDEX KEY: 0001599014 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 231373307 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-31 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001599014 Roth David C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-10-31 4 M 0 18875 A 18875 D Common Stock 2023-11-01 4 F 0 6301 2.22 D 12574 D Restricted Stock Units 2023-10-31 4 M 0 18875 0.00 D Common Stock 18875 18875 D Represents shares of common stock received upon vesting of a restricted stock unit award. Represents shares used to cover tax withholding on a restricted stock unit release. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024. /s/ Todd Rosenthal, as attorney-in-fact 2023-11-02